Report Library
All Reports
Diabetes KOL Insight Report
July 01, 2012
KOL Highlights
- Albiglutide (GSK) weight loss data not clinically meaningful
- Level of nausea will be the major difference in these GLP-1 drugs
- Believes Glymera (PhaseBio) injection lasts the longest and stands out from the others
- ITCA 650 (Intarcia) the subcutaneous pellet is the biggest competition
| Indications Covered: | Diabetes Mellitus, Type II |